Fundraising Fox
MicroTransponder
NASDAQ: MOBIAustin, US · Founded 2007 · Delaware corporation · 253 employees on LinkedIn · 4 known investors
Find your way into MicroTransponder
Sign up to see every warm intro you have to MicroTransponder
- Paths you didn't know you had: your email and LinkedIn already hold routes to the MicroTransponder team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Mobia Medical (formerly MicroTransponder) develops Vivistim Paired VNS Therapy, an FDA-approved treatment for stroke survivors with moderate to severe upper extremity impairment. The company delivers clinically validated recovery solutions specifically for chronic ischemic stroke patients.
Founders & leadership
Board
NB
Nelson Bunker CurnesBoard director
TJ
Thomas Jordan Curnes IIBoard director
CT
DM
Dana MeadBoard director
BH
Bill HarringtonBoard director
CL
Cythia LuccheseBoard director
TJ
Thomas J. CurnesBoard director
CM
Chuck MiddlekaufBoard director
Investors · 4
Longitude Capitallisted by Longitude CapitalMenlo Park · $10M – $30M
How we know: the VCSheet dataset · Not right? Tell us
UT Horizon Fundlisted by UT Horizon FundAustin
How we know: UT Horizon Fund's portfolio page · funding news · Not right? Tell us
Green Park & Golf VenturesreportedDallas · $500K – $2M
How we know: funding news · Not right? Tell us
US Venture PartnersreportedMenlo Park · $500K – $10Mvia Casey Tansey · board
How we know: board seat on SEC Form D · funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$108.2M disclosed across 7 of 8 rounds · 1900–2025
▶$32.5MraisedMar 2025 · 19 investors · Other Health CareRule 506(b)
▶$32.5MraisedMar 2025 · 19 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Richard John FoustExecutive Officer, Director
- Nelson Bunker CurnesExecutive Officer, Director
- Thomas Jordan Curnes IIExecutive Officer, Director
- Casey TanseyDirector
- Dana MeadDirector
- Bill HarringtonDirector
- Cythia LuccheseDirector
- Offering amount
- $65M
- Amount sold
- $32.5M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$42.9MraisedSep 2022 · 41 investors · Other Health CareRule 506(b)
▶$42.9MraisedSep 2022 · 41 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Thomas Jordan Curnes IIExecutive Officer, Director
- Bill HarringtonDirector
- Casey TanseyDirector
- Richard John FoustExecutive Officer, Director
- Nelson Bunker CurnesExecutive Officer, Director
- Offering amount
- $72.9M
- Amount sold
- $42.9M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedAug 2021 · 18 investors · Other Health CareRule 506(b)
▶$6MraisedAug 2021 · 18 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Nelson Bunker CurnesExecutive Officer, Director
- Thomas Jordan Curnes IIExecutive Officer, Director
- Thomas CurnesDirector
- Chuck MiddlekaufDirector
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.8MraisedSep 2020 · 11 investors · Other Health CareRule 506(b)
▶$5.8MraisedSep 2020 · 11 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Nelson Bunker CurnesDirector
- Thomas J. CurnesDirector
- T. Jordan Curnes IIExecutive Officer, Director
- Chuck MiddlekaufDirector
- Frank McEachernExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $5.8M
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.6MraisedNov 2017 · 21 investors · Other Health CareRule 506(b)
▶$11.6MraisedNov 2017 · 21 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Frank McEachernExecutive Officer, Director
- Chuck MiddlekaufDirector
- Thomas J. CurnesDirector
- N. Bunker CurnesDirector
- T. Jordan Curnes IIExecutive Officer, Director
- Offering amount
- $16.6M
- Amount sold
- $11.6M
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedJul 2017 · 20 investors · Other Health CareRule 506(b)
▶$5.5MraisedJul 2017 · 20 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Chuck MiddlekaufDirector
- N. Bunker CurnesDirector
- Frank McEachernExecutive Officer, Director
- Thomas J. CurnesDirector
- T. Jordan Curnes IIExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $5.5M
- First sale
- May 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.9MraisedSep 2015 · 18 investors · Other Health CareRule 506(b)
▶$3.9MraisedSep 2015 · 18 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Thomas J. CurnesDirector
- Chuck MiddlekaufDirector
- Frank McEachernExecutive Officer, Director
- N. Bunker CurnesDirector
- T. Jordan Curnes IIExecutive Officer, Director
- Offering amount
- $5.5M
- Amount sold
- $3.9M
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $224.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2012 | $2.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2011 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2010 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $286.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $175K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $239K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $96.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2008 | $113.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does MicroTransponder do?
- Mobia Medical (formerly MicroTransponder) develops Vivistim Paired VNS Therapy, an FDA-approved treatment for stroke survivors with moderate to severe upper extremity impairment. The company delivers clinically validated recovery solutions specifically for chronic ischemic stroke patients.
- Who are MicroTransponder's investors?
- MicroTransponder's investors include Longitude Capital, UT Horizon Fund, Green Park & Golf Ventures, US Venture Partners.
- How much funding has MicroTransponder raised?
- MicroTransponder has disclosed $108.2M raised across 7 of its 8 known rounds.
- Where is MicroTransponder headquartered?
- MicroTransponder is headquartered in Austin, US.